Pharmaceutical - AstraZeneca, Patents


Current filters:


Popular Filters

DC Circuit Court says AstraZeneca not entitled to three-year exclusivity for Seroquel


In a brief opinion handed down last week by the US Court of Appeals for the District of Columbia Circuit,…

AstraZenecaNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel

European Patent Office maintains Pozen's PA/Vimovo patent


US drug firm Pozen (Nasdaq: POZN) says that the Opposition Division of the European Patent Office has…

AstraZenecaEuropeInflammatory diseasesPatentsPharmaceuticalPozenVimovo

Further savings expected following Australian Crestor patent decision, says GMiA


In a decision brought down by the Australian Federal Court earlier this week, suppliers of generic medicines…


AstraZeneca's Crestor patent rule invalid in Australia


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that the Federal Court of Australia…


US Court of Appeals confirms validity of AstraZeneca' Seroquel XR patent


AstraZeneca announced that, on 14 February 2013, the United States Court of Appeals for the Federal Circuit…

AstraZenecaGenericsLegalNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XR

EU Court of Justice dismisses AstraZeneca appeal on patent settlement


The European Union's highest court, the Court of Justice, yesterday dismissed the appeal of Anglo-Swedish…


Germany invalidates Seroquel patent; Merck drops combo diabetes drug development


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

Slow-down of European bipolar therapy market set for short-term slowdown


Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth…

AstraZenecaEuropeGenericsMarkets & MarketingNeurologicalPatentsPharmaceuticalPricingSeroquel

US Court upholds AstraZeneca Seroquel XR patent


In some good news for the company, Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last night…

Anchen PharmaceuticalsAstraZenecaGenericsMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XRTorrent Pharmaceuticals

US court turns down AstraZeneca FDA injunction; Teva debuts generic Seroquel in UK


In another setback for Anglo-Swedish drug major AstraZeneca in its fight to delay generic competition…

AstraZenecaEuropeGenericsLegalNeurologicalNorth AmericaPatentsPharmaceuticalRegulationSeroquelSeroquel XR

AstraZeneca Seroquel XR patent ruled invalid in UK; eyeing Forest buy?


In another setback regarding intellectual property on its blockbuster antipsychotic drug, AstraZeneca…

AstraZenecaEuropeForest LaboratoriesLegalNeurologicalPatentsPharmaceuticalSeroquel XR

EU Commission finds no evidence against AstraZeneca and Nycomed


The European Commission said yesterday that it has ceased its antitrust investigation into the pharmaceutical…

AstraZenecaEuropeLegalNycomedPatentsPharmaceuticalRegulationTakeda Pharmaceuticals

Back to top